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doi:10.1016/j.ejvs.2009.11.009Abstract Objectives: To evaluate the early outcomes following thoracoabdominal aortic
aneurysm (TAAA) repair utilising fenestrated and branched endografts.
Design and materials and methods: A prospective analysis of all patients undergoing endovas-
cular repair of TAAA in a single academic centre. All patients were deemed unfit for open
surgical repair. Customised endografts were designed using CT data reconstructed on 3D
workstations. Post-operatively all patients were evaluated radiologically at hospital discharge,
at 6, 12, 18 and 24 months, and annually thereafter.
Results: Thirty-three consecutive patients (30 males) were treated over 33 months (August
2006 to April 2009). Median age and aneurysm size were 70 years (range 50e83 years) and
64 mm (range 55e100 mm) respectively. 114/116 (98%) of the targeted visceral vessels were
successfully catheterised and perfused. The in-hospital mortality rate was 9% (3/33). Transient
spinal cord ischaemia was diagnosed in 4/33 (12%) patients, and permanent paraplegia in one
(3%). The median follow-up period was 11 months (range 1e33 months). Endoleaks were iden-
tified in 5/33 (15%) patients: type II in four patients and a type III endoleak in one patient
which required the only secondary intervention. During follow-up, two patients died: one from
stroke and the other from myocardial infarction 9 and 29 months respectively after the
procedure.
Conclusion: This preliminary study, which includes our learning curve, confirms the feasibility
and safety of the endovascular repair of TAAA in high-risk patients. Meticulous follow-up to
assess sac behaviour and visceral perfusion is critical in order to ensure optimal results of these
complex endovascular repairs requiring numerous mating components.
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Table 1 Patient characteristics and aneurysm morphology.
Patient demographics Median age (years) 70 (range 50e83)
Male gender 30/33
Comorbidities ASA grade III or higher (%) 25/33 (76)
Hypertension (%) 19/33 (58)
Coronary artery disease (%) 15/33 (45)
Left ventricular ejection fraction<35% (%) 8/33 (24)
Diabetes mellitus (%) 2/33 (6)
COPD (%) 14/33 (42)
Home oxygen (%) 3/33 (9)
Baseline creatinine > 1.5 mg/dl (%) 7/33 (21)
Prior aortic surgery (%) 10/33 (30.3)
Aneurysm characteristics Crawford type I (%) 1 (3)
Crawford type II (%) 7 (21)
Crawford type III (%) 12 (37)
Crawford type IV (%) 13 (39)
Median maximal diameter (mm) 64 (range 55e100)
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The 5-year survival and repair-free survival rates for large
(>6 cm) thoracoabdominal aneurysms (TAAA) managed
non-operatively are 39% and 17% respectively.1 The annual
rupture rate in this setting is estimated at 14%,2 indicating
that this condition represents a considerable risk to life.
The first operative repair of a TAAA was described by
Etheridge in 19553 and since then, despite advances to limit
morbidity and mortality, complication rates remain high.
Mortality rates vary between 3% and 21% in the published
literature and when national and regional registry figures
are analysed, the figure is invariably toward the upper end
of this spectrum.4e6 Spinal cord ischaemia (SCI) occurs in
between 4% and 11% of patients.4e6 The risk of paraplegia
in patients with type II TAAA can rise to 25% in low-volume
hospitals and in places where no adjunctive methods such
as distal aortic perfusion or neurological monitoring are
performed. Cardiopulmonary and renal morbidity are also
high with renal failure requiring dialysis occurring in up to
15% of cases.7 Because of these high morbidity and
mortality rates alternative approaches have been sought,
with two approaches currently under evaluation. In the
first, the ‘‘hybrid approach’’, visceral perfusion is safe-
guarded by means of an extra-anatomic bypass followed by
endovascular exclusion of the entire aneurysm. This
approach has the advantage of limiting the exposure
required to a laparotomy while avoiding a thoracotomy,
although in unfit patients this remains a considerable
undertaking. Early results8e10 in terms of mortality, SCI and
morbidity rates generated great enthusiasm. Unfortu-
nately, more recently reported data11,12 are less favourable
with morbidity and mortality rates comparable to those of
the standard open surgical technique. Currently, the hybrid
technique is restricted to patients with no other reasonable
options, such as emergency cases or high-risk patients with
anatomy unfavourable for a branched endograft.
The second technique in evolution is a totally endovas-
cular approach utilising specifically constructed branched
modular aortic grafts. The rationale for this approach grew
out of good initial experience with fenestrated grafts
developed to treat juxta-renal aneurysms by endovascularmeans.13 Preservation of visceral flow is achieved by means
of either fenestrations or branches or a combination of both
on the component deployed in the region of the visceral
arteries. Standard aortic grafts are deployed proximally
and distally to achieve exclusion of the aneurysm sac.
Design of these individualised grafts is technically
demanding, requiring three-dimensional reconstruction of
thin-slice CT images on a workstation to allow accurate
orientation of the fenestrations or branches toward their
target vessel in all planes. Initial reports of the technique
have all been from single-centre studies and are non-
randomised and confined to patients deemed unfit for open
repair. Published 30-day mortality rates range from 5.5% to
9.1% in the larger series with rates of 0e25% in the smaller
series.14e23 Rates of SCI and cardiopulmonary and renal
morbidities appear to be largely in concordance with rates
observed following open repair, despite the endovascular
patients being an inherently less robust population medi-
cally. In summary, despite the complexity of this technique,
experience worldwide is increasing abreast with overall
experience with endovascular techniques in general, and
outcomes in unfit patients appear similar to those achieved
with open surgery in fit patients.24 With these factors in
mind we wish to present our medium-term results with the
first 33 cases performed at our institution in order to add
these data to the growing body of evidence in favour of this
technique.
Materials and methods
From August 2006 to July 2009, 33 consecutive patients
with thoracoabdominal aortic aneurysm treated with
custom-designed branched endovascular devices were
evaluated in a prospective fashion. Written informed
consent was obtained from all patients. Preoperative
assessment included cardiac stress tests and selective
coronary angiography based on the results, trans-thoracic
echocardiography, pulmonary function testing, routine
blood work, and physical examination. All patients enrolled
were considered unfit for open surgery. Patient character-
istics are outlined in Table 1. No patients presenting with
connective tissue disease were included.
Figure 1 3D-VR reconstruction of the post-procedure CT
scan of a device with four reinforced fenestrations. This design
was used to treat a type III thoracoabdominal aneurysm
developed after previous type IV TAAA open tubular repair. The
aortic lumen was narrow at the level of the visceral arteries
allowing the use of four reinforced fenestrations mated with
Advanta stent grafts (Atrium Medical Corporation, Hudson, NH,
USA).
Figure 2 Six-month follow-up CT scan of a four-branched
device used to treat a type III TAAA which developed 12 years
after aorto-bi-iliac open repair of an infra-renal AAA. In this
case the large aortic lumen (10 cm) allowed the use of four
caudally oriented branches mated with Fluency grafts (CR
Bard, Murray Hill, NJ, USA) to perfuse the visceral vessels.
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used to evaluate the entire aorta and images were assessed
on a 3D imaging work station (Aquarius WS, Terarecon Inc,
Mateo, CA, USA).
Device construct
Fenestrated endografts have been developed to compen-
sate for poor proximal (infra-renal) sealing zones in the
case of juxta-renal abdominal aortic aneurysms. Current
early reports describing this technique and its clinical
outcome are very favourable.25e32 At present, these
devices are only manufactured by Cook Medicalª (Bloo-
mington, USA) and the Zenith endograft forms the basis of
this device. A ‘‘CE mark’’ has been issued, and the devices
are currently undergoing FDA clinical trials in the USA to
confirm their safety and efficacy. More recently endografts
with side branches sewn to the graft fabric have been
developed and a wide range of endografts combining
fenestrations and branches can now be manufactured to
very precisely match the anatomy of complex TAAAs.
Fenestrations consist of a circular opening in the graft
fabric circumferentially reinforced with a nitinol ring which
is mated with a balloon-expandable stent graft deployed
into the target vessel. Directional side branches consist of
a 6- or 8-mm polyester graft sewn to the aortic prosthesis
above the target vessel which is mated with a self-
expandable stent graft deployed in the target vessel.
A detailed description of TAAA endograft design and
implantation technique has been described elsewhere.33 It
can be briefly summarised as follows:Device design
Device lengths and visceral vessel positions were calculated
from the centrelines of flow reconstructions. The general
concept can be summarized as follows:
- The proximal and distal sealing zones of the device are
positioned over healthy arterial segments (>20 mm).
- If the gap between the deployed endograft and the
aortic wall bearing the target vessel is less than 10 mm,
fenestrations are employed (Fig. 1). If this gap is
>10 mm, then the target vessels are perfused using
branches (Fig. 2). In the same endograft it is possible to
combine fenestrations and branches (Fig. 3).
- The anatomy of the target vessel also has an impact on
the endograft design. When the angulation between
the aorta and the target vessel is <60, selective
catheterisation of this vessel through a fenestration,
via femoral access, can be challenging. In this setting,
the diameter of the aortic endograft can be reduced to
accommodate a branch and facilitate access to the
target vessel via a brachial approach.
- Large overlapping segments between the various
endograft components and between the bridging stent
grafts and fenestrations or branches are required if
type III endoleaks are to be avoided.Implantation technique
Open or percutaneous access is required to both common
femoral arteries. On one side, the main body of the graft is
introduced. When the endograft has been designed with
Figure 3 Anterior view of a 3D reconstruction of a type I
thoracoabdominal aneurysm treated with an endovascular
graft with two branches and two reinforced fenestrations. The
celiac and superior mesenteric branches are perfused by
helical oriented branches. They are mated with the visceral
vessels with a Fluency graft (CR Bard, Murray Hill, NJ, USA).
The renal arteries were incorporated into the repair with
reinforced fenestrations mated with Advanta stent grafts
(Atrium Medical Corporation, Hudson, NH, USA).
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contralateral side, over a stiff wire. Under fluoroscopy the
fenestrations, branches and the associated markers are
recognised and the orientation of the main body of the
device is checked. The fenestrated/branched body is
inserted over this stiff wire to the required position so that
the appropriate fenestrations are correctly aligned with
their matching target vessels (checked by repeated angi-
ographies with small volumes of contrast). The outer sheath
of the delivery system is withdrawn. Through the contra-
lateral large sheath, access to the lumen of the endograft is
obtained. A side branch access sheath is then advanced on
this wire and catheterisation of a target vessel through its
appropriate fenestration performed. The access sheath is
then advanced into the vessel over a stiff wire. The
manoeuvre is repeated for each target vessel and its
fenestration. Once the stent grafts are all positioned in
their target vessels through the fenestrations, the diameter
reducing ties of the endograft are released. The bridging
stent grafts are positioned with 3e4 mm protruding in the
aorta and expanded once the access sheath has been
withdrawn. The aortic extremity of the bridging stent is
flared with a 12-mm-diameter, 2-cm-long balloon.
When the endograft’s design includes one or more
branches, a hydrophilic wire is then advanced in the
branch-preloaded catheter until it is in the descending
thoracic aorta. A snare is advanced through a brachial
sheath to capture the wire from the preloaded catheter, to
create through-and-through access from the groin to the
brachial artery. Over this wire, from the brachial access,a 10 Fr sheath is advanced into the endograft and ulti-
mately into the side branch. The target vessel is then
selectively catheterised. When a stiff wire has been posi-
tioned in the target vessel, the through-and-through wire is
retrieved. This latter manoeuvre is necessary to advance
the brachial sheath and subsequently the bridging stent
graft into the target vessel. The bridging stent graft over-
laps completely the branch of the endograft and is posi-
tioned at least 2 cm into the target vessel.
The fenestrated/branched component is then connected
to other proximal or distal aortic components as planned,
being careful not to dislodge or disrupt the existing device,
or the fenestration stents.
Perioperative patient management
Hydration and N-acetyl cysteine were administered before
and after the procedures. During the procedure we
routinely used red cell and plasma transfusions to reduce
the risk of disseminated intravascular coagulopathy.
Patients were routinely followed in an intensive care unit
for a minimum of 12 h and spinal drainage was selectively
employed depending on extent of aortic coverage or in the
setting of prior aortic repair. In patients without neuro-
logical symptoms CSF pressure was maintained at 10 mmHg
during the first 48 h, draining a maximum of 30 ml/h of CSF.
In patients with neurological symptoms, we reduced CSF
pressure to <5 mmHg. We maintained a mean arterial
pressure >90 mmHg to augment spinal cord perfusion
during the first 72 h post-operatively.
Follow-up
Patients underwent 64-slice CTA before discharge. Follow-
up clinical assessment, laboratory testing (including eGFR
evaluation), CTA, duplex ultrasonography, and plain chest
and abdominal radiographs were performed at 1, 6, 12, 18
and 24 months, and yearly thereafter.
Results
Device
A total of 81 fenestrations and 35 branches were designed
to perfuse the target vessels. An additional nine scallop
fenestrations were positioned on the top of the branched/
fenestrated endograft to allow access to the endograft
lumen from a brachial approach (with an indwelling cath-
eter). The target vessels were perfused with branches only
in seven patients, with fenestrations only in 14 patients,
and with a combination of branches and fenestrations in 12
patients.
Procedure
There were no conversions to open repair. We were unable
to catheterise a right renal artery in two patients: this was
corrected using a bypass in one patient (performed during
the same procedure after the endovascular phase was
completed), but in the other we elected to proceed without
Table 2 Post-operative complications.
Complication N (%)
Death 3 (9)
Paraparesis (transient) 4 (12)
Paraplegia 1 (3)
Transient dialysis 3 (9)
Pneumonia 2 (6)
Atrial fibrillation 1 (3)
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post-operative day (POD) 11 from respiratory failure).
Completion angiography confirmed patency in 114 of the
116 (98%) target vessels (including the ilio-renal bypass). In
addition to the abandoned right renal artery, there was one
instance of celiac trunk occlusion. No further target vessel
occlusion was depicted on the discharge CT.
Both cases of failed right renal access (including the first
patient of our series) occurred in a similar setting, i.e. with
the inability to correctly orientate the endograft due to
a severely angulated visceral aorta.
Median operative time, media volume, and fluoroscopy
dose were 232 min (range 120e390), 190 ml (range 76e
300), and 9.8 mBcq/m2 (range 7.2e15.3) respectively.
Mortality
In-hospital mortality rate was 9% (3/33).
- After a prolonged procedure (320 min), the patient with
failed catheterisation of the right renal artery devel-
oped bronchial bleeding associated with significant
thrombocytopenia. He died from respiratory failure on
POD 11. This obese patient had a past history of left
lung lobectomy and COPD.
- One patient died 3 days after an uncomplicated
procedure. She developed cardiac failure with subse-
quent renal failure requiring haemodialysis. Troponin T
remained in normal range (<0.25 ng/ml). Haemoglobin
level was stable and there was no evidence of hae-
morrhage. A trans-thoracic echocardiogram (TTE)
revealed a global wall motion abnormality with a mean
ejection fraction (EF) of 30%. Prior to surgery, stress
echocardiography had been performed. This exam
revealed no wall motion abnormalities, no thoracic
pain, and no ECG changes. The diagnosis of stress
cardiomyopathy, or catecholamine induced cardiomy-
opathy, was hypothesised. This condition occurs in the
absence of any other etiology, and in the setting of
recent surgery that induces intense activation of the
sympathetic nervous system.
- One patient died on POD 31. Sustained hypotension
following the retrieval of the branched-endograft
delivery system was noted intra-operatively. A right
common iliac artery rupture was confirmed by an
angiogram and a compliant balloon was subsequently
inflated in the distal aorta before a retroperitoneal
approach was undertaken. An ilio-femoral bypass was
required to repair the right common iliac artery
rupture. She developed multi-organ failure with liver
and renal failure that required haemodialysis.Morbidity
The median intensive care unit and hospital stays were
3.6 days (range 0e30 days) and 8.6 days (range 6e14 days)
respectively.
All post-operative complications are summarised in
Table 2.
Neurological complications
Only one patient (3%) developed permanent paraplegia. He
was the third patient treated in our institution. The
procedure was the second longest (360 min) in our experi-
ence. Although there was no prolonged hypotension, large
sheaths in both iliac arteries occluded arterial flow to both
internal iliacs and to the lower limbs for a prolonged time.
He had a type II TAAA but no prophylactic spinal drainage
had been performed. Since then, spinal drainage has been
routine for type I, II, and III TAAAs.
Four patients (12%) experienced transient lower
extremity weakness and numbness (two bilateral, two
unilateral neurological deficit), from which they recovered
during hospitalisation or in the early follow-up period. One of
these was a case of delayed transient paraparesis which
occurred 30 days after the procedure. This patient had been
discharged on POD 7 after an uneventful post-operative
course. When he was readmitted, he was dehydrated. His
systolic arterial pressure was <100 mmHG. The paraparesis
was reversed by administration of intravenous fluids. His
antihypertensive treatment was subsequently modified.
All patients suffering neurological sequelae had exten-
sive aortic aneurysms (three type II and two type III).
Renal complications
Three patients required haemodialysis after the procedure:
- Both aforementioned patients that developed fatal
multi-organ failure;
- A patient with preoperative renal insufficiency. He was
discharged with an eGFR back to its preoperative level
and did not require any further dialysis after a 12-
month follow-up period.
Sustained elevation of serum creatinine greater than
30% over baseline level was noted in one patient (3%) at
1-month follow-up.
Endoleaks and secondary intervention
Endoleaks were identified in 5/33 (15%) patients: type II in
four patients and a type III endoleak in one patient. Only
one secondary procedure was performed for a type III
endoleak in the first patient of the series in whom we had
performed a right ilio-renal bypass. The 6-months CT scan
diagnosed sac enlargement and a persistent type III endo-
leak from the right renal fenestration (which we had failed
to catheterise) and also from the joint between the supe-
rior mesenteric artery fenestration and its bridging stent
graft. We covered the renal fenestration with an aortic cuff
and added an SMA bridging stent graft. The CT scan after
the secondary procedure confirmed the absence of endo-
leak but his last CT scan performed 29 months after the
initial procedure showed a probable type II endoleak.
176 S. Haulon et al.All four type II endoleaks remained patent during the
follow-up period but none was associated with sac
enlargement.
No aneurysm ruptures were reported and only the soli-
tary aforementioned case of sac enlargement requiring




The median follow-up period was 11 months (range 1e
33 months). No patients were lost to follow-up. During
follow-up, two patients died: one from stroke and the other
from myocardial infarction 9 and 29 months respectively
after the procedure.
Device integrity and branch patency
During the follow-upperiod, no component separations, barb
or stent fractures, or device migrations were detected.
All renal and visceral branch vessels (109/109) patent at
hospital discharge remained patent on the consecutive
follow-up exams.
Discussion
Despite advances in surgical technique and perioperative
care, the morbidity and mortality associated with open
repair of TAAA remains high. This makes the decision to
intervene in patients diagnosed with TAAA a complex one
which requires cognisance of multiple factors including the
natural history of TAAA, the patient’s general condition,
the available surgical expertise and the patient’s wishes.
Many patients, particularly older patients are deemed unfit
for open surgical repair of TAAA and it is this cohort of
patients that has been studied so far in the growing expe-
rience of endovascular repair of these lesions. Intuitively,
one would expect a particularly poor outcome for such
patients undergoing such a procedure, but interestingly this
does not appear to be the case.
The rapid evolution of imaging technology, and indeed
materials technology, has permitted extremely precise
visualisation of the anatomy of such aneurysms and the
design of highly specific grafts tailored to suit almost every
anatomical variation encountered with regard to the
visceral arteries. Experience published to date varies from
centre to centre with regard to the nature of devices used,
with Chuter’s21 series for example using branch grafts
exclusively. Conversely, Bicknell has routinely used fenes-
trated grafts only when repairing TAAA.23 In our current
series we have been flexible in our approach using
a combination of both types of branch to the visceral
arteries. So far it is fair to say that the published data is not
of sufficient volume to support the use of any one of these
three approaches over another.
What would appear to be very clear from all authors is
that the design and construction of the device is of critical
importance, and indeed is probably the single biggest
factor in successfully attaining perfusion of the target
vessels. To this end fine-slice CT and 3D reconstruction
facilities are mandatory.Mortality rates in fit patients undergoing open TAAA
repair approach 20% when one looks at national or regional
registry figures, although in some of the larger series from
high-volume centres this can be improved to between 5%
and 12%.34e36
Published mortality figures for endovascular repair of
TAAA generally range between 5.5% and 9.1% in the larger
series, although one series of four patients had a mortality
of 25% and other series of between one and nine patients
reported 0% mortality.17e19,22,23 In our series of 33 patients
the 30-day mortality was 9%, a figure which is concordant
with the other larger series published to date.
Spinal cord ischaemia and consequent paraplegia/para-
paresis is the most feared morbidity of both open and
endovascular approaches. This complication is reported to
occur in 4e11% of cases undergoing open repair of TAAA.4e6
The largest series of endovascular repair of TAAA by Roselli
reported a 2.7% paraplegia rate (2/73 patients) with both
patients dying subsequently.16 A larger series from the same
centre which included both TAAA and thoracic aortic aneu-
rysms included 352 patients treated by endovascular tech-
niques and showed a SCI rate of 4.3%, the risk for these
patients being particularly associated with prior aortic
surgery.24 Chuter21 reported zero incidence of SCI in his
series of 22 patients, while Verhoeven36 reports SCI in 5/30
patients for an incidence of 16.7% with four recovering fully.
In our own series 5/33 patients showed evidence of SCI for an
incidence of 15.2%. Four of these patients had paraparesis
only and made a full recovery with spinal fluid drainage or
blood pressure augmentation, while one patient developed
paraplegia without recovery. All of these cases occurred in
patients with extensive aneurysms (mostly type II TAAA).
Renal complications were uncommon in our series with
only one patient (3%) demonstrating a persistent elevation
serum creatinine of more than 30% over baseline at 1-
month follow-up. Three patients (9.1%) required transient
dialysis perioperatively. These figures compare very
favourably with those quoted for open TAAA repair where
up to 15% may require dialysis.7
In the current series only one secondary intervention
was required for a persistent type III endoleak associated
with sac enlargement in a patient whose right renal artery
could not be cannulated at the time of initial endovascular
repair and in whom an ilio-renal bypass was accordingly
performed. This was successfully treated by deploying an
aortic cuff across the fenestration when sac enlargement
was detected. There was no other case of sac enlargement
and four type II endoleaks remain under surveillance.
It is worth bearing in mind that our series (and
presumably other published series to date) included our
‘‘learning curve’’ and that it is likely that, as further
experience is gained, outcomes will improve further. Also
this series, in common with the other published series,
included only patients deemed unfit for open surgical repair
and compared outcomes with the open procedure in
patients who were inherently healthier. Despite this
significant disparity between the compared groups,
outcomes appear at least similar.
Our current practice for patients with TAAA is to eval-
uate both the patient’s physiological status and the
morphology of the aorta and its branches. For example
a 55-year old man with a dissecting aneurysm will be
Repair of Aortic Aneurysms 177recommended open surgery. We consider that it is uneth-
ical at this stage to treat a fit patient by an endovascular
approach even if the anatomy is favourable for such
a treatment, although our position will probably change
when long-term data become available. On the other
hand, an old patient (>75 years old) with diffuse athero-
sclerotic disease will be recommended to undergo endo-
vascular repair if his anatomy is favourable for such
a procedure, which is usually the case nowadays. If no
complete endovascular option is possible, we will search
for a limited hybrid option, combining, for example,
a hepato-right renal bypass to a fenestrated/branched
endograft implantation if the contra-indication for
a complete endovascular treatment was challenging right
renal artery anatomy. We tend to avoid the classic ‘‘hybrid
option’’ (combining a complete extra-anatomic visceral
debranching and aortic endografting) as in our hands this
has not provided better results than a classic open repair in
high-risk patients. We have only performed such a classic
hybrid approach during the study period in two patients
presenting with ruptured TAAA and strict contra-indication
to left thoracotomy.
Conclusion
The current study adds further to the growing body of
evidence in favour of an endovascular approach to the
repair of TAAA. This study, which was carried out in an
inherently high-risk patient group, suggests that the tech-
nique is safe when compared to published data for open
approaches in healthier patients. The endovascular
approach appears to be durable in the short to medium
term with acceptable secondary re-intervention rates.Conflict of Interest
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